Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-22-057397
Filing Date
2022-11-16
Accepted
2022-11-16 19:10:43
Documents
1
Period of Report
2022-11-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 15109
  Complete submission text file 0001209191-22-057397.txt   16450
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Issuer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address
Masson Kristina (Reporting) CIK: 0001950501 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41551 | Film No.: 221396510